3-iodobenzylguanidine has been researched along with camptothecin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K | 1 |
| Bryant, HE; Helleday, T; Jemth, AS; Karlberg, T; Lehtiö, L; Loseva, O; Schüler, H | 1 |
| Chesler, L; DuBois, SG; Goodarzian, F; Groshen, S; Hawkins, R; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Shimada, H; Stewart, C; Tagen, M; Tsao-Wei, D; Villablanca, JG; Yanik, G | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Allen, S; Bent, M; Courtier, J; DuBois, SG; Hawkins, R; Hilton, JF; Hollinger, F; Matthay, KK; Mosse, YP | 1 |
2 trial(s) available for 3-iodobenzylguanidine and camptothecin
| Article | Year |
|---|---|
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Prognosis; Tissue Distribution; Vincristine; Young Adult | 2012 |
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Radiotherapy Dosage; Vincristine; Young Adult | 2015 |
3 other study(ies) available for 3-iodobenzylguanidine and camptothecin
| Article | Year |
|---|---|
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2008 |
PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.
Topics: 3-Iodobenzylguanidine; Adenosine Diphosphate Ribose; Camptothecin; Cell Cycle Proteins; DNA; DNA Breaks, Single-Stranded; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Histones; Humans; Hydrolysis; Hydroxylamine; Mercuric Chloride; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Structure, Tertiary; RNA, Small Interfering; Topoisomerase I Inhibitors | 2010 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |